Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 TENET
HEALTHCARE CORPORATION 
 4.625% Senior Secured First Lien Notes due 2024 

unconditionally guaranteed as to the 

payment of principal, premium, 

if any, and interest by the 

Guarantors named on Schedule I hereto 
  

 

Exchange and Registration Rights Agreement 

June 14, 2017 
 Barclays Capital Inc. 

745 Seventh Avenue 
 New York, NY 10019 

As Representative of the Initial Purchasers 
 Ladies and
Gentlemen: 
 Tenet Healthcare Corporation, a Nevada corporation (the “Company”), issued on the Closing Date (as defined herein),
$830,000,000 in aggregate principal amount of its 4.625% Senior Secured First Lien Notes due 2024 (the “Initial Notes”) and if the Completion Date (as defined in the Indenture referred to below) occurs will issue $1,040,000,000
aggregate principal amount of its additional 4.625% Senior Secured First Lien Notes due 2024 (the “Additional Notes”; the Initial Notes and, if issued, the Additional Notes are referred to herein collectively as the
“Notes”). The Notes are unconditionally guaranteed by the Guarantors (as defined herein), upon the terms and conditions set forth in that certain Offering Memorandum, dated June 5, 2017, and that certain Purchase Agreement (the
“Purchase Agreement”), dated as of June 5, 2017, among the Company, the subsidiaries of the Company set forth on the signature pages thereto (the “Guarantors”) and Barclays Capital Inc., Merrill Lynch, Pierce,
Fenner & Smith Incorporated, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., Wells Fargo Securities, LLC, RBC Capital Markets, LLC, SunTrust Robinson Humphrey, Inc., Capital One Securities, Inc., Morgan Stanley &
Co. LLC and Scotia Capital (USA) Inc. (collectively the “Initial Purchasers”). As an inducement to purchase the Notes, and in satisfaction of a condition to the obligations of the Company under the Purchase Agreement, the Company
and the Guarantors agree with the Initial Purchasers, for the benefit of the holders (as defined herein) from time to time of the Registrable Securities (as defined herein), as follows: 

1. Certain Definitions. For purposes of this Exchange and Registration Rights Agreement (this “Agreement”), the following
terms shall have the following respective meanings: 
 “Additional Notes” shall have the meaning assigned thereto in
the preamble. 

 “Base Indenture” shall mean the indenture, dated as of November 6, 2001
between the Company and The Bank of New York Mellon Trust Company N.A., as successor trustee to The Bank of New York, as Trustee. 

“Base Interest” shall mean the interest that would otherwise accrue on the Securities under the terms thereof and the
Indenture, without giving effect to the provisions of this Agreement. 
 The term “broker-dealer” shall mean any broker or
dealer registered with the Commission under the Exchange Act. 
 “Business Day” shall have the meaning set forth in Rule
13e-4(a)(3) promulgated by the Commission under the Exchange Act, as the same may be amended or succeeded from time to time. 

“Closing Date” shall mean June 14, 2017, which is the date of original issuance of the Securities. 

“Commission” shall mean the United States Securities and Exchange Commission, or any other federal agency at the time
administering the Exchange Act or the Securities Act, whichever is the relevant statute for the particular purpose. 

“Company” shall have the meaning assigned thereto in the preamble. 

“Consummation Date” shall have the meaning assigned thereto in Section 2(a) hereof. 

“Effective Time” shall mean the time and date as of which the Commission declares the Exchange Registration Statement
effective or as of which the Exchange Registration Statement otherwise becomes effective. 
 “Exchange Act” shall mean the
Securities Exchange Act of 1934, as amended, or any successor thereto, as the same may be amended or succeeded from time to time. 

“Exchange Offer” shall have the meaning assigned thereto in Section 2(a) hereof. “Exchange Registration” shall
have the meaning assigned thereto in Section 3(c) hereof. 
 “Exchange Registration Statement” shall have the meaning
assigned thereto in Section 2(a) hereof. 
 “Exchange Securities” shall have the meaning assigned thereto in
Section 2(a) hereof. 
 “FINRA” shall mean the Financial Industry Regulatory Authority, Inc. 

“Free Trade Date” shall mean the 380th day following the Closing Date. 

“Freely Tradable” shall mean, with respect to the Securities at any time of determination. that (a) all outstanding
Securities are eligible to be sold by a person who has not been an “affiliate” (as defined in Rule 405 under the Securities Act) of the Company or any Guarantor 

  
 2 

 
during the preceding 90 days without any volume or manner of sale restrictions under the Securities Act, (b) the Company has provided a certificate to the Trustee instructing the Trustee
that the restrictive legend on the Securities no longer applies and (c) the Securities have been assigned an unrestricted CUSIP number. 

“Guarantors” shall have the meaning assigned thereto in the preamble. 

The term “holder” shall mean each of the persons who acquire Registrable Securities from time to time (including any
successors or assigns), in each case for so long as such person owns any Registrable Securities. 
 “Indenture” shall mean
the Base Indenture, as supplemented by the Supplemental Indenture. 
 “Initial Notes” shall have the meaning assigned
thereto in the preamble. 
 “Initial Purchasers” shall mean Barclays Capital Inc., Merrill Lynch, Pierce, Fenner &
Smith Incorporated, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., Wells Fargo Securities, LLC, RBC Capital Markets, LLC, SunTrust Robinson Humphrey, Inc., Capital One Securities, Inc., Morgan Stanley & Co. LLC and Scotia
Capital (USA) Inc. 
 “Notes” shall have the meaning assigned thereto in the preamble. 

The term “person” shall mean any individual, corporation, partnership, limited liability company, joint venture, trust,
unincorporated organization or government or any agency or political subdivision thereof. 
 “Purchase Agreement” shall
have the meaning assigned thereto in the preamble. 
 “Registrable Securities” shall mean the Securities; provided,
however, that a Security shall cease to be a Registrable Security upon the earliest to occur of the following: (a) in the circumstances contemplated by Section 2(a) hereof, the Security has been exchanged for an Exchange Security in
an Exchange Offer as contemplated in Section 2(a) hereof (provided that any Exchange Security that, pursuant to the second to last and third to last sentences of Section 2(a), is included in a prospectus for use in connection with
resales by broker-dealers shall be deemed to be a Registrable Security with respect to Sections 5, 6 and 9 until resale of such Registrable Security has been effected within the Resale Period); (b) the Securities become Freely Tradable or
(c) such Security shall cease to be outstanding. 
 “Registration Default” shall have the meaning assigned thereto in
Section 2(b) hereof. 
 “Registration Default Period” shall have the meaning assigned thereto in Section 2(b)
hereof. 
 “Registration Expenses” shall have the meaning assigned thereto in Section 4 hereof. 

“Representative” shall mean Barclays Capital Inc. 

  
 3 

 “Resale Period” shall have the meaning assigned thereto in Section 2(a)
hereof. 
 “Restricted Holder” shall mean (i) a holder that is an affiliate of the Company within the meaning of Rule
405, (ii) a holder who acquires Exchange Securities outside the ordinary course of such holder’s business, (iii) a holder who has arrangements or understandings with any person to participate in the Exchange Offer for the purpose of
distributing Exchange Securities and (iv) a holder that is a broker-dealer, but only with respect to Exchange Securities received by such broker-dealer pursuant to an Exchange Offer in exchange for Registrable Securities acquired by the
broker-dealer directly from the Company. 
 “Rule 144,” “Rule 405,” “Rule 415” and
“Rule 433” shall mean, in each case, such rule promulgated by the Commission under the Securities Act (or any successor provision), as the same may be amended or succeeded from time to time. 

“Securities” shall mean the Notes, and securities issued in exchange therefor or in lieu thereof pursuant to the Indenture.
Each Security is entitled to the benefit of the guarantees provided for in the Indenture (the “Guarantees”) and, unless the context otherwise requires, any reference herein to a “Security,” an “Exchange Security”
or a “Registrable Security” shall include the related Guarantees. 
 “Securities Act” shall mean the Securities
Act of 1933, as amended, or any successor thereto, as the same may be amended or succeeded from time to time. 
 “Special
Interest” shall have the meaning assigned thereto in Section 2(b) hereof. 
 “Supplemental Indenture” shall
mean the twenty-ninth supplemental indenture, dated as of June 14, 2017, between the Company, the Guarantors and the Trustee, as the same shall be supplemented or amended from time to time. 

“Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended, or any successor thereto, and the rules,
regulations and forms promulgated thereunder, all as the same may be amended or succeeded from time to time. 
 “Trustee”
shall mean The Bank of New York Mellon Trust Company, N.A., as trustee under the Indenture, together with any successors in such capacity. 

Unless the context otherwise requires, any reference herein to a “Section” or “clause” refers to a Section or clause, as
the case may be, of this Agreement, and the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. 

2. Registration Under the Securities Act. (a) Subject to the last sentence of this Section 2(a), if the Securities have not become
Freely Tradable on or before the Free Trade Date, the Company and the Guarantors agree to use all commercially reasonable efforts to (i) file under the Securities Act a registration statement relating to an offer to exchange (such registration
statement, the “Exchange Registration Statement,” and such offer, the “Exchange Offer”) any and all of the Securities for a like 

  
 4 

 
aggregate principal amount of debt securities issued by the Company and guaranteed by the Guarantors, which debt securities and guarantees are substantially identical to the Securities and the
related Guarantees, respectively (and are entitled to the benefits of a trust indenture that is substantially identical to the Indenture or is the Indenture and that has been qualified under the Trust Indenture Act), except that they have been
registered pursuant to an effective registration statement under the Securities Act and do not contain provisions for the additional interest contemplated in Section 2(b) below (such new debt securities are hereinafter called “Exchange
Securities”), (ii) cause the Exchange Registration Statement to become effective under the Securities Act, (iii) commence the Exchange Offer promptly after such Exchange Registration Statement has become effective, (iv) hold
the Exchange Offer open for at least 20 Business Days (or longer if required by applicable law) after the date that notice of the Exchange Offer is mailed to holders of the Securities, (v) exchange Exchange Securities for all Registrable
Securities that have been properly tendered and not withdrawn on or prior to the expiration of the Exchange Offer and (vi) consummate the Exchange Offer on the earliest practicable date after the Exchange Registration Statement has become
effective, but in no event later than 30 Business Days thereafter (such 30th Business Day being the “Consummation Date”). The Exchange Offer will be registered under the Securities Act on the appropriate form and will comply with
all applicable tender offer rules and regulations under the Exchange Act. The Exchange Offer will be deemed to have been “completed” only (A) if the debt securities and related guarantees received by holders other than Restricted
Holders in the Exchange Offer for Registrable Securities are, upon receipt, transferable by each such holder without restriction under the Securities Act and the Exchange Act and without material restrictions under the blue sky or securities laws of
a substantial majority of the states of the United States of America, and (B) upon the earlier to occur of (1) the Company having exchanged the Exchange Securities for all outstanding Registrable Securities pursuant to the Exchange Offer
and (2) the Company having exchanged, pursuant to the Exchange Offer, Exchange Securities for all Registrable Securities that have been properly tendered and not withdrawn before the expiration of the Exchange Offer, which shall be on a date
that is at least 20 Business Days following the commencement of the Exchange Offer. The Company and the Guarantors agree (I) to include in the Exchange Registration Statement a prospectus for use in any resales by any holder of Exchange
Securities that is a broker-dealer and (II) to keep such Exchange Registration Statement effective for a period (the “Resale Period”) beginning when Exchange Securities are first issued in the Exchange Offer and ending upon the
earlier of the expiration of the 180th day after the Exchange Offer has been completed or such time as such broker-dealers no longer own any Registrable Securities. With respect to such Exchange Registration Statement, such holders shall have the
benefit of the rights of indemnification and contribution set forth in Sections 6(a), (b), (c) and (d) hereof. The obligations of the Company and the Guarantors set forth in this Section 2(a) shall cease on the date on which the
Securities become Freely Tradable. 
 (b) If (i) the Exchange Offer has not been consummated prior to the Consummation Date,
(ii) the Securities have not become Freely Tradable on or before the Free Trade Date, or (iii) any Exchange Registration Statement required by this Agreement is filed and declared effective, but shall thereafter cease to be effective or
fail to be usable for its intended purpose without being succeeded by a post-effective amendment or prospectus supplement to such Exchange Registration Statement that cures such failure and that is itself declared effectively promptly (each such
event referred to in clauses (i) through (iii), a “Registration Default,” and the period during which a Registration Default has occurred and is continuing, the “Registration

  
 5 

 
Default Period”), then, as liquidated damages for such Registration Default, subject to the provisions of Section 8(b), special interest (“Special Interest”), in
addition to the Base Interest, shall accrue at a per annum rate of 0.25% for the first 90 days of the Registration Default Period, at a per annum rate of 0.50% for the second 90 days of the Registration Default Period, at a per annum rate of 0.75%
for the third 90 days of the Registration Default Period and at a per annum rate of 1.0% thereafter for the remaining portion of the Registration Default Period, provided that in no event shall the Company be required to pay Special Interest
for more than one Registration Default at any given time. The Registration Default Period shall terminate on the date on which (i) the Securities become Freely Tradable or (ii) the Exchange Registration Statement has been declared
effective and the Exchange Offer has been consummated. Special Interest shall not accrue as a result of the Company’s failure to provide a certificate to the Trustee instructing the Trustee that the restrictive legend on the Securities no
longer applies unless the Company has received a request to do so by a holder of Securities or the Trustee on or after the 380th day after the Closing Date; provided that if the Company receives such a request on or after the fifth Business Day
immediately preceding the Free Trade Date and the restrictive legend on the Securities has not been removed by the close of business on the fifth Business Day thereafter, Special Interest shall accrue as provided in this Section 2(b) until the
date on which (i) the Securities become Freely Tradable or (ii) the Exchange Registration Statement has been declared effective and the Exchange Offer has been consummated. 

(c) The Company shall take, and shall cause the Guarantors to take, all actions necessary or advisable to be taken to ensure that the
transactions contemplated herein are effected as so contemplated, including all actions necessary or desirable to register the Guarantees under the Exchange Registration Statement contemplated in Section 2(a) hereof. 

(d) Any reference herein to a registration statement or prospectus as of any time shall be deemed to include any document incorporated, or
deemed to be incorporated, therein by reference as of such time and any reference herein to any post-effective amendment to a registration statement or to any prospectus supplement as of any time shall be deemed to include any document incorporated,
or deemed to be incorporated, therein by reference as of such time. 
 3. Registration Procedures. 

If the Company and the Guarantors file a registration statement pursuant to Section 2(a), the following provisions shall apply: 

(a) At or before the Effective Time of the Exchange Registration, the Company and the Guarantors shall qualify the Indenture under the Trust
Indenture Act. 
 (b) In the event that such qualification would require the appointment of a new trustee under the Indenture, the Company
and the Guarantors shall appoint a new trustee thereunder pursuant to the applicable provisions of the Indenture. 
 (c) In connection with
the Company’s and the Guarantors’ obligations with respect to the registration of Exchange Securities as contemplated by Section 2(a) (the “Exchange Registration”), if applicable, the Company and the Guarantors shall,
as soon as practicable (or as otherwise specified): 

  
 6 

 (i) prepare and file with the Commission an Exchange Registration Statement on
any form that may be utilized by the Company and the Guarantors and that shall permit the Exchange Offer and resales of Exchange Securities by broker-dealers during the Resale Period to be effected as contemplated by Section 2(a), and use all
commercially reasonable efforts to cause such Exchange Registration Statement to become effective; 
 (ii) prepare and file
with the Commission such amendments and supplements to such Exchange Registration Statement and the prospectus included therein as may be necessary to effect and maintain the effectiveness of such Exchange Registration Statement for the periods and
purposes contemplated in Section 2(a) hereof and as may be required by the applicable rules and regulations of the Commission and the instructions applicable to the form of such Exchange Registration Statement, and promptly provide each
broker-dealer holding Exchange Securities with such number of copies of the prospectus included therein (as then amended or supplemented), in conformity in all material respects with the requirements of the Securities Act and the Trust Indenture Act
and the rules and regulations of the Commission thereunder, as such broker-dealer reasonably may request prior to the expiration of the Resale Period, for use in connection with resales of Exchange Securities; 

(iii) notify each broker-dealer that has requested or received copies of the prospectus included in such Exchange Registration
Statement, and confirm such advice in writing, (A) when such Exchange Registration Statement or the prospectus included therein or any prospectus amendment or supplement or post-effective amendment has been filed, and, with respect to such
Exchange Registration Statement or any post-effective amendment, when the same has become effective, (B) of any comments by the Commission and by the blue sky or securities commissioner or regulator of any state with respect thereto or any
request by the Commission for amendments or supplements to such Exchange Registration Statement or prospectus or for additional information, (C) of the issuance by the Commission of any stop order suspending the effectiveness of such Exchange
Registration Statement or the initiation or threatening of any proceedings for that purpose, (D) if at any time the representations and warranties of the Company and the Guarantors contemplated by Section 5 cease to be true and correct in
all material respects, (E) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Exchange Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such
purpose, or (F) at any time during the Resale Period when a prospectus is required to be delivered under the Securities Act, that such Exchange Registration Statement, prospectus, prospectus amendment or supplement or post-effective amendment
does not conform in all material respects to the applicable requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder or contains an untrue statement of a material fact or omits to
state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(iv) in the event that the Company and the Guarantors would be required, pursuant to Section 3(c)(iii)(F) above, to
notify any broker-dealers holding Exchange Securities, prepare and furnish to each such holder a reasonable number of copies of a 

  
 7 

 
prospectus supplemented or amended so that, as thereafter delivered to purchasers of such Exchange Securities during the Resale Period, such prospectus shall conform in all material respects to
the applicable requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder and shall not contain an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(v) use all commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of such
Exchange Registration Statement or any post-effective amendment thereto at the earliest practicable date; 
 (vi) use all
commercially reasonable efforts to (A) register or qualify the Exchange Securities under the securities laws or blue sky laws of such jurisdictions as are contemplated by Section 2(a) no later than the commencement of the Exchange Offer,
(B) keep such registrations or qualifications in effect and comply with such laws so as to permit the continuance of offers, sales and dealings therein in such jurisdictions until the expiration of the Resale Period and (C) take any and
all other actions as may be reasonably necessary or advisable to enable each broker-dealer holding Exchange Securities to consummate the disposition thereof in such jurisdictions; provided, however, that neither the Company nor any of the Guarantors
shall be required for any such purpose to (1) qualify as a foreign corporation in any jurisdiction wherein it would not otherwise be required to qualify but for the requirements of this Section 3(c)(vi), (2) consent to general service
of process in any such jurisdiction or (3) in the case of the Company, make any changes to its certificate of incorporation or bylaws or any agreement between it and its stockholders, and in the case of the Guarantors, make any changes to
(x) the certificate (or articles) of incorporation, certificate (or articles) of organization, certificate (or articles) of formation or certificate of limited partnership, as the case may be, and any amendments thereto, of any Guarantor,
(y) the bylaws, limited liability company agreement, operating agreement or partnership agreement, as the case may be, and any amendments thereto, of any Guarantor or (z) any agreement between any Guarantor and its stockholders,
shareholders, members or partners; 
 (vii) use all commercially reasonable efforts to obtain the consent or approval of
each governmental agency or authority, whether federal, state or local, that may be required to effect the Exchange Registration, the Exchange Offer and the offering and sale of Exchange Securities by broker-dealers during the Resale Period; 

(viii) provide a CUSIP number for all Exchange Securities, not later than the applicable Effective Time; and 

(ix) comply with all applicable rules and regulations of the Commission, and make generally available to its security holders
as soon as practicable but no later than 18 months after the Effective Time of such Exchange Registration Statement, an earnings statement of the Company and its subsidiaries complying with Section 11(a) of the Securities Act (including, at the
option of the Company, Rule 158 thereunder). 

  
 8 

 (d) Until the expiration of one year after the Closing Date, the Company and the Guarantors will
not, and will not permit any of their “affiliates” (as defined in Rule 144) to, resell any of the Securities that have been acquired by any of them except pursuant to an effective registration statement under the Securities Act. 

4. Registration Expenses. 

The Company and the Guarantors agree to bear and to pay or cause to be paid promptly all expenses incident to the Company’s and the
Guarantors’ performance of or compliance with this Agreement, including, without limitation, (a) all Commission and any FINRA registration, filing and review fees and expenses including fees and disbursements of counsel for the placement
or sales agent or underwriters in connection with such registration, filing and review; (b) all expenses relating to the preparation, printing, production, distribution and reproduction of each registration statement required to be filed
hereunder, each prospectus included therein or prepared for distribution pursuant hereto, each amendment or supplement to the foregoing, the expenses of preparing the Securities for delivery and the expenses of printing or producing any blue sky or
legal investment memoranda and all other documents in connection with the offering, sale or delivery of Securities to be disposed of (including certificates representing the Securities); (c) messenger, telephone and delivery expenses relating
to the offering, sale or delivery of Securities and the preparation of documents referred in clause (b) above; (d) fees and expenses of the Trustee under the Indenture, any agent of the Trustee and any counsel for the Trustee and of any
collateral agent or custodian; (e) internal expenses (including all salaries and expenses of the Company’s or Guarantors’ officers and employees performing legal or accounting duties); (f) fees, disbursements and expenses of
counsel and independent registered public accountants of the Company (including the expenses of any opinions or “comfort” letters required by or incident to such performance and compliance); (g) any fees charged by securities rating
services for rating the Securities; and (h) fees, expenses and disbursements of any other persons, including special experts, retained by the Company or its Guarantors in connection with this Agreement (collectively, the “Registration
Expenses”). To the extent that any reasonable fees are incurred, assumed or paid by any holder of Registrable Securities or its counsel, the Company or its Guarantors shall reimburse such person for the full amount of such reasonable fees so
incurred, assumed or paid promptly after receipt of a request therefor. Notwithstanding the foregoing, the holders of the Registrable Securities being registered shall pay all agency fees and commissions attributable to the sale of such Registrable
Securities. 
 5. Representations and Warranties. 

Each of the Company and the Guarantors, jointly and severally, represents and warrants to, and agrees with, the Initial Purchasers and each of
the holders from time to time of Registrable Securities that: 
 (a) Each registration statement covering Registrable Securities and each
prospectus (including any preliminary or summary prospectus) contained therein or furnished pursuant to Section 3(c) hereof and any further amendments or supplements to any such registration statement or prospectus, when it becomes effective or
is filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder and will not

  
 9 

 
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; and at all times
subsequent to the Effective Time when a prospectus would be required to be delivered under the Securities Act, other than from (i) such time as a notice has been given to holders of Registrable Securities pursuant to Section 3(c)(iii)(F)
hereof until (ii) such time as the Company furnishes an amended or supplemented prospectus pursuant to Section 3(c)(iv) hereof, each such registration statement, and each prospectus (including any summary prospectus) contained therein or
furnished pursuant to Section 3(c) hereof, as then amended or supplemented, will conform in all material respects to the requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder
and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; provided,
however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by a holder of Registrable Securities expressly for use
therein. 
 (b) Any documents incorporated by reference in any prospectus referred to in Section 5(a) hereof, when they become
or became effective or are or were filed with the Commission, as the case may be, will conform or conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and none of such documents will
contain or contained an untrue statement of a material fact or will omit or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this
representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by a holder of Registrable Securities expressly for use therein. 

(c) The compliance by the Company and the Guarantors with all of the provisions of this Agreement and the consummation of the transactions
herein contemplated will not: (i) conflict with or result in a material breach of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any subsidiary of the Company is a party or by which the Company or any subsidiary of the Company is bound or to which any of the property or assets of the Company or any subsidiary of the Company is subject; (ii) result in any
violation of the provisions of the articles of incorporation, as amended, or the bylaws of the Company; the certificate (or articles) of incorporation, certificate (or articles) of organization, certificate (or articles) of formation or certificate
of limited partnership, as the case may be, and any amendments thereto, of any Guarantor; the bylaws, limited liability company agreement, operating agreement or partnership agreement, as the case may be, and any amendments thereto, of any
Guarantor; or (iii) result in any material violation of any law or statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any subsidiary of the Company or any of their
properties. No consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the consummation by the Company and the Guarantors of the transactions contemplated by
this Agreement, except the registration under the Securities Act of the Securities, the qualification of the Indenture under the Trust Indenture Act and such consents, approvals, authorizations, registrations or qualifications as may be required
under state securities or blue sky laws in connection with the offering and distribution of the Securities. 

  
 10 

 (d) This Agreement has been duly authorized, executed and delivered by the Company and each
Guarantor. 
 6. Indemnification. 

(a) Indemnification by the Company and the Guarantors. The Company and the Guarantors, jointly and severally, will indemnify and hold
harmless each of the holders of Registrable Securities included in an Exchange Registration Statement, and each person who participates as a placement or sales agent or as an underwriter in any offering or sale of such Registrable Securities against
any losses, claims, damages or liabilities, joint or several, to which such holder, agent or underwriter may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Exchange Registration Statement under which such Registrable Securities were registered under the Securities Act, or any preliminary,
final or summary prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule 433) contained therein or furnished by the Company to any such holder, agent or underwriter, or any amendment or supplement
thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such holder, such agent and
such underwriter for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that neither the Company nor any
Guarantor shall be liable to any such person in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in any
registration statement contemplated hereunder, or preliminary, final or summary prospectus (including, without limitation, any “issuer free writing prospectus” as defined in Rule 433), or amendment or supplement thereto, in reliance upon
and in conformity with written information furnished to the Company by such person expressly for use therein. 
 (b) Notices of Claims,
Etc. Promptly after receipt by an indemnified party under subsection (a) above of written notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party
pursuant to the indemnification provisions of or contemplated by this Section 6, notify such indemnifying party in writing of the commencement of such action; but the omission so to notify the indemnifying party shall not relieve it from any
liability which it may have to any indemnified party otherwise than under the indemnification provisions of or contemplated by Section 6(a) hereof. In case any such action shall be brought against any indemnified party and it shall notify an
indemnifying party of the commencement thereof, such indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with
counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its
election so to assume the defense thereof, such indemnifying party shall not be liable to such indemnified party for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in
connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the prior 

  
 11 

 
written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of
which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of
the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 

(c) Contribution. If for any reason the indemnification provisions contemplated by Section 6(a) are unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party
as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party in connection with the statements or
omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified party shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such indemnifying party or by such indemnified party,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contributions pursuant to this
Section 6(c) were determined by pro rata allocation (even if the holders or any agents or underwriters or all of them were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable
considerations referred to in this Section 6(c). The amount paid or payable by an indemnified party as a result of the losses, claims, damages, or liabilities (or actions in respect thereof) referred to above shall be deemed to include any
legal or other fees or expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 6(c), no holder shall be required to contribute
any amount in excess of the amount by which the dollar amount of the proceeds received by such holder from the sale of any Registrable Securities (after deducting any fees, discounts and commissions applicable thereto) exceeds the amount of any
damages that such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, and no underwriter shall be required to contribute any amount in excess of the amount by which the
total price at which the Registrable Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such underwriter has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The holders’ obligations in this Section 6(c) to contribute shall be several in proportion to the principal amount of Registrable Securities registered by them and not joint. 

(d) The obligations of the Company and the Guarantors under this Section 6 shall be in addition to any liability which the Company or the
Guarantors may otherwise have and shall extend, upon the same terms and conditions, to each officer, director and partner of each holder, 

  
 12 

 
agent and underwriter and each person, if any, who controls any holder, agent or underwriter within the meaning of the Securities Act; and the obligations of the holders and any agents or
underwriters contemplated by this Section 6 shall be in addition to any liability which the respective holder, agent or underwriter may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the
Company or any Guarantor (including any person who, with his consent, is named in any registration statement as about to become a director of the Company or any Guarantor) and to each person, if any, who controls the Company within the meaning of
the Securities Act. 
 7. Rule 144. 

The Company covenants to the holders of Registrable Securities that to the extent it shall be required to do so under the Exchange Act, the
Company shall timely file the reports required to be filed by it under the Exchange Act or the Securities Act (including the reports under Section 13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1) of Rule 144 adopted by the
Commission under the Securities Act) and the rules and regulations adopted by the Commission thereunder, and shall take such further action as any holder of Registrable Securities may reasonably request, all to the extent required from time to time
to enable such holder to sell Registrable Securities without registration under the Securities Act within the limitations of the safe harbor provided by Rule 144 under the Securities Act, as such Rule may be amended from time to time, or any similar
or successor rule or regulation hereafter adopted by the Commission. Upon the request of any holder of Registrable Securities in connection with that holder’s sale pursuant to Rule 144, the Company shall deliver to such holder a written
statement as to whether it has complied with such requirements. 
 8. Miscellaneous. 

(a) No Inconsistent Agreements. The Company and each Guarantor represents, warrants, covenants and agrees that it has not granted, and
shall not grant, registration rights with respect to Registrable Securities or any other securities which would be inconsistent with the terms contained in this Agreement. 

(b) Specific Performance. The parties hereto acknowledge that there would be no adequate remedy at law if the Company or any Guarantor
fails to perform any of its obligations hereunder and that the Initial Purchasers and the holders from time to time of the Registrable Securities may be irreparably harmed by any such failure, and accordingly agree that the Initial Purchasers and
such holders, in addition to any other remedy to which they may be entitled at law or in equity, shall be entitled to seek specific performance of the obligations of the Company and the Guarantors under this Agreement in accordance with the terms
and conditions of this Agreement, in any court of the United States or any state thereof having jurisdiction. 
 (c) Notices. All
notices, requests, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered by hand, if delivered personally or by courier, or three days after being deposited in the
mail (registered or certified mail, postage prepaid, return receipt requested) as follows: If to the Company, to it at 1445 Ross Avenue, Suite 1400, Dallas, Texas 75202, Attention: Paul Castanon, Deputy General Counsel, and if to a holder, to the
address of such holder set forth in the security register or other records of the Company, or to such other address as the Company or any such holder may have furnished to the other in writing in accordance herewith, except that notices of change of
address shall be effective only upon receipt. 

  
 13 

 (d) Parties in Interest. All the terms and provisions of this Agreement shall be binding
upon, shall inure to the benefit of and shall be enforceable by the parties hereto and the holders from time to time of the Registrable Securities and the respective successors and assigns of the parties hereto and such holders. In the event that
any transferee of any holder of Registrable Securities shall acquire Registrable Securities, in any manner, whether by gift, bequest, purchase, operation of law or otherwise, such transferee shall, without any further writing or action of any kind,
be deemed a beneficiary hereof for all purposes and such Registrable Securities shall be held subject to all of the terms of this Agreement, and by taking and holding such Registrable Securities such transferee shall be entitled to receive the
benefits of, and be conclusively deemed to have agreed to be bound by all of the applicable terms and provisions of this Agreement. If the Company shall so request, any such successor, assign or transferee shall agree in writing to acquire and hold
the Registrable Securities subject to all of the applicable terms hereof. 
 (e) Survival. The respective indemnities, agreements,
representations, warranties and each other provision set forth in this Agreement or made pursuant hereto shall remain in full force and effect regardless of any investigation (or statement as to the results thereof) made by or on behalf of any
holder of Registrable Securities, any director, officer or partner of such holder, any agent or underwriter or any director, officer or partner thereof, or any controlling person of any of the foregoing, and shall survive delivery of and payment for
the Registrable Securities pursuant to the Purchase Agreement and the transfer and registration of Registrable Securities by such holder and the consummation of an Exchange Offer. 

(f) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York. 
 (g) Headings. The descriptive headings of the several sections and paragraphs of this Agreement are inserted for
convenience only, do not constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. 

(h) Entire Agreement; Amendments. This Agreement and the other writings referred to herein (including the Indenture, the Purchase
Agreement and the form of Securities) or delivered pursuant hereto which form a part hereof contain the entire understanding of the parties with respect to its subject matter. This Agreement supersedes all prior agreements and understandings between
the parties with respect to its subject matter. This Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written
instrument duly executed by the Company, the Guarantors and the holders of at least a majority in aggregate principal amount of the Registrable Securities at the time outstanding. Each holder of any Registrable Securities at the time or thereafter
outstanding shall be bound by any amendment or waiver effected pursuant to this Section 8(h), whether or not any notice, writing or marking indicating such amendment or waiver appears on such Registrable Securities or is delivered to such
holder. 

  
 14 

 (i) Inspection. For so long as this Agreement shall be in effect, this Agreement and a
complete list of the names and addresses of all the holders of Registrable Securities shall be made available for inspection and copying on any Business Day by any holder of Registrable Securities for proper purposes only (which shall include any
purpose related to the rights of the holders of Registrable Securities under the Securities, the Indenture and this Agreement) at the offices of the Company at the address thereof set forth in Section 8(c) above and at the office of the Trustee
under the Indenture. 
 (j) Counterparts. This Agreement may be executed by the parties in counterparts, each of which shall be
deemed to be an original, but all such respective counterparts shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by telecopier, facsimile or other electronic transmission
(i.e., a “pdf’ or “tif’) shall be effective as delivery of a manually executed counterpart thereof. 
 (k)
Severability. If any provision of this Agreement, or the application thereof in any circumstance, is held to be invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of such provision in
every other respect and of the remaining provisions contained in this Agreement shall not be affected or impaired thereby. 
 (signature
pages follow) 

  
 15 

 If the foregoing is in accordance with your understanding, please sign and return to us two
counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the holders, this letter and such acceptance hereof shall constitute a binding agreement among each of the holders, the Guarantors and the Company. 

 
  

					
	Very truly yours,
	
	TENET HEALTHCARE CORPORATION
		
	By:	 	/s/ James E. Snyder III
		 	Name:	 	James E. Snyder III
		 	Title:	 	Vice President and Assistant Treasurer

  
 [Signature Page to
Exchange and Registration Rights Agreement] 

 AMERICAN MEDICAL (CENTRAL), INC. 

AMI INFORMATION SYSTEMS GROUP, INC. 

AMISUB (HEIGHTS), INC. 

AMISUB (HILTON HEAD), INC. 

AMISUB (SFH), INC. 

AMISUB (TWELVE OAKS), INC. 

AMISUB OF NORTH CAROLINA, INC. 

AMISUB OF SOUTH CAROLINA, INC. 

AMISUB OF TEXAS, INC. 

ANAHEIM MRI HOLDING, INC. 

BROOKWOOD HEALTH SERVICES, INC. 

CGH HOSPITAL, LTD., by: CORAL GABLES HOSPITAL, INC., as general partner 

COASTAL CAROLINA MEDICAL CENTER, INC. 

COMMUNITY HOSPITAL OF LOS GATOS, INC. 

CORAL GABLES HOSPITAL, INC. 

CYPRESS FAIRBANKS MEDICAL CENTER INC. 

DELRAY MEDICAL CENTER, INC. 
 DES
PERES HOSPITAL, INC. 
 EAST COOPER COMMUNITY HOSPITAL, INC. 

FMC MEDICAL, INC. 
 FOUNTAIN VALLEY REGIONAL HOSPITAL AND MEDICAL
CENTER 
 FRYE REGIONAL MEDICAL CENTER, INC. 
 GOOD SAMARITAN
MEDICAL CENTER, INC. 
 HEALTHCARE NETWORK CFMC, INC. 

HEALTHCARE NETWORK HOLDINGS, INC. 
 HEALTHCORP NETWORK, INC. 

HEALTHCARE NETWORK LOUISIANA, INC. 
 HEALTHCARE NETWORK MISSOURI,
INC. 
 HEALTHCARE NETWORK TEXAS, INC. 
 HEALTH SERVICES NETWORK
HOSPITALS, INC. 
 HEALTH SERVICES NETWORK TEXAS, INC. 
 HIALEAH
HOSPITAL, INC. 
 HILTON HEAD HEALTH SYSTEM, L.P., by: TENET PHYSICIAN SERVICES – HILTON HEAD, INC., as general partner

 HOSPITAL DEVELOPMENT OF WEST PHOENIX, INC. 

LIFEMARK HOSPITALS, INC. 
 LIFEMARK HOSPITALS OF FLORIDA, INC.

 NEW MEDICAL HORIZONS II, LTD., by: CYPRESS FAIRBANKS MEDICAL CENTER INC., as general partner 

NORTH SHORE MEDICAL CENTER, INC. 

ORNDA HOSPITAL CORPORATION 

PALM BEACH GARDENS COMMUNITY HOSPITAL, INC. 

SAINT FRANCIS HOSPITAL – BARTLETT, INC. 

SLH VISTA, INC. 

SPALDING REGIONAL MEDICAL CENTER, INC. 

SRRMC MANAGEMENT, INC. 
  

  
 [Signature Page to
Exchange and Registration Rights Agreement] 

 ST. MARY’S MEDICAL CENTER INC. 

SYLVAN GROVE HOSPITAL, INC. 

TENET CALIFORNIA, INC. 
 TENET
FLORIDA, INC. 
 TENET HEALTHSYSTEM HAHNEMANN, L.L.C., by: TENET HEALTHSYSTEM PHILADELPHIA, INC., as managing member 

TENET HEALTHSYSTEM MEDICAL, INC. 

TENET HEALTHSYSTEM PHILADELPHIA, INC. 

TENET HEALTHSYSTEM ST. CHRISTOPHER’S HOSPITAL FOR CHILDREN, L.L.C., by: TENET HEALTHSYSTEM PHILADELPHIA, INC., as
managing member 
 TENET HOSPITALS LIMITED, by: HEALTHCARE NETWORK TEXAS, INC., as general partner 

TENET PHYSICIAN SERVICES — HILTON HEAD, INC. 

TH HEALTHCARE, LTD., by: LIFEMARK HOSPITALS, INC., as general partner 

VHS ACQUISITION CORPORATION 
 VHS
ACQUISITION SUBSIDIARY NUMBER 1, INC. 
 VHS ACQUISITION SUBSIDIARY NUMBER 3, INC. 

VHS ACQUISITION SUBSIDIARY NUMBER 7, INC. 

VHS ACQUISITION SUBSIDIARY NUMBER 9, INC. 

VHS BROWNSVILLE HOSPITAL COMPANY, LLC 

WEST BOCA MEDICAL CENTER, INC. 

VHS CHILDREN’S HOSPITAL OF MICHIGAN, INC. 

VHS DETROIT RECEIVING HOSPITAL, INC. 

VHS HARLINGEN HOSPITAL COMPANY, LLC 

VHS HARPER-HUTZEL HOSPITAL, INC. 

VHS HURON VALLEY-SINAI HOSPITAL, INC. 

VHS OF ARROWHEAD, INC. 
 VHS OF
ILLINOIS, INC. 
 VHS REHABILITATION INSTITUTE OF MICHIGAN, INC. 

VHS SAN ANTONIO PARTNERS, LLC, by: VHS ACQUISITION SUBSIDIARY NUMBER 5, INC., its managing member, and VHS HOLDING COMPANY,
INC. 
 VHS SINAI-GRACE HOSPITAL, INC. 

VHS VALLEY MANAGEMENT COMPANY, INC. 

VHS WEST SUBURBAN MEDICAL CENTER, INC. 

VHS WESTLAKE HOSPITAL, INC. 
 VHS
OF PHOENIX, INC. 
 VANGUARD HEALTH FINANCIAL COMPANY, LLC 

VANGUARD HEALTH HOLDING COMPANY I, LLC 

VANGUARD HEALTH HOLDING COMPANY II, LLC 

VANGUARD HEALTH MANAGEMENT, INC. 

VANGUARD HEALTH SYSTEMS, INC. 

VHS OF MICHIGAN, INC. 
  

					
	 By:
	 	/s/ James E. Snyder III
		 	Name:	 	James E. Snyder III
		 	Title:	 	Treasurer

  
 [Signature Page to
Exchange and Registration Rights Agreement] 

 BBH BMC, LLC 

BROOKWOOD BAPTIST HEALTH 1, LLC 
 DESERT REGIONAL MEDICAL CENTER,
INC. 
 DOCTORS HOSPITAL OF MANTECA, INC. 
 DOCTORS MEDICAL
CENTER OF MODESTO, INC. 
 JFK MEMORIAL HOSPITAL, INC. 

LAKEWOOD REGIONAL MEDICAL CENTER, INC. 
 LOS ALAMITOS MEDICAL
CENTER, INC. 
 PLACENTIA-LINDA HOSPITAL, INC. 
 SAN RAMON
REGIONAL MEDICAL CENTER, LLC 
 SIERRA VISTA HOSPITAL, INC. 

TWIN CITIES COMMUNITY HOSPITAL, INC. 
 VHS VALLEY HEALTH SYSTEM,
LLC 
  

					
	 By:
	 	/s/ James E. Snyder III
		 	Name:	 	James E. Snyder III
		 	Title:	 	Assistant Treasurer

 ATLANTA MEDICAL CENTER, INC. 

NORTH FULTON MEDICAL CENTER, INC. 
  

					
	 By:
	 	/s/ William G. Morrison
		 	Name:	 	William G. Morrison
		 	Title:	 	Treasurer

  
 [Signature Page to
Exchange and Registration Rights Agreement] 

 The foregoing Agreement is hereby confirmed and accepted as of the date first above written. 

 

	
	 BARCLAYS CAPITAL INC.

Acting on behalf of itself

and as Representative of

the several Initial Purchasers

 BARCLAYS CAPITAL INC. 
  

					
	By:	 	 /s/ John Skrobe

		 	Name:	 	John Skrobe
		 	Title:	 	Managing Director

  
 [Signature Page to
Exchange and Registration Rights Agreement] 

 Schedule I 

Guarantors 
 American Medical (Central),
Inc. 
 AMI Information Systems Group, Inc. 
 Amisub (Heights),
Inc. 
 Amisub (Hilton Head), Inc. 
 Amisub (SFH), Inc. 

Amisub (Twelve Oaks), Inc. 
 Amisub of North Carolina, Inc. 

Amisub of South Carolina, Inc. 
 Amisub of Texas, Inc. 

Anaheim MRI Holding, Inc. 
 BBH BMC, LLC 

Atlanta Medical Center, Inc. 
 Brookwood Baptist Health 1, LLC

 Brookwood Health Services, Inc. 
 CGH Hospital, Ltd. 

Coastal Carolina Medical Center, Inc. 
 Community Hospital of Los
Gatos, Inc. 
 Coral Gables Hospital, Inc. 
 Cypress Fairbanks
Medical Center, Inc. 
 Delray Medical Center, Inc. 
 Des Peres
Hospital, Inc. 
 Desert Regional Medical Center, Inc. 
 Doctors
Hospital of Manteca, Inc. 
 Doctors Medical Center of Modesto, Inc. 

East Cooper Community Hospital, Inc. 
 FMC Medical, Inc. 

Fountain Valley Regional Hospital and Medical Center 
 Frye
Regional Medical Center, Inc. 
 Good Samaritan Medical Center, Inc. 

Healthcare Network CFMC, Inc. 
 Healthcare Network Holdings, Inc.

 Healthcare Network Louisiana, Inc. 
 Healthcare Network
Missouri, Inc. 
 Healthcare Network Texas, Inc. 
 HealthCorp
Network, Inc. 
 Health Services Network Hospitals, Inc. 

Health Services Network Texas, Inc. 
 Hialeah Hospital, Inc. 

Hilton Head Health System, L.P. 
 Hospital Development of West
Phoenix, Inc. 
 JFK Memorial Hospital, Inc. 

  
 I-1 

 Lakewood Regional Medical Center, Inc. 

Lifemark Hospitals of Florida, Inc. 
 Lifemark Hospitals, Inc.

 Los Alamitos Medical Center, Inc. 
 New Medical Horizons II,
Ltd. 
 North Fulton Medical Center, Inc. 
 North Shore Medical
Center, Inc. 
 OrNda Hospital Corporation 
 Palm Beach Gardens
Community Hospital, Inc. 
 Placentia-Linda Hospital, Inc. 

Saint Francis Hospital – Bartlett, Inc. 
 San Ramon Regional
Medical Center, LLC 
 Sierra Vista Hospital, Inc. 
 SLH Vista,
Inc. 
 Spalding Regional Medical Center, Inc. 
 SRRMC
Management, Inc. 
 St. Mary’s Medical Center Inc. 
 Sylvan
Grove Hospital, Inc. 
 Tenet California, Inc. 
 Tenet Florida,
Inc. 
 Tenet HealthSystem Hahnemann, LLC 
 Tenet HealthSystem
Medical, Inc. 
 Tenet HealthSystem Philadelphia, Inc. 
 Tenet
HealthSystem St. Christopher’s Hospital for Children, L.L.C. 
 Tenet Hospitals Limited 

Tenet Physician Services – Hilton Head, Inc. 
 TH Healthcare,
Ltd. 
 Twin Cities Community Hospital, Inc. 
 Vanguard Health
Financial Company, LLC 
 Vanguard Health Holding Company I, LLC 

Vanguard Health Holding Company II, LLC 
 Vanguard Health
Management, Inc. 
 Vanguard Health Systems, Inc. 
 VHS
Acquisition Corporation 
 VHS Acquisition Subsidiary Number 1, Inc. 

VHS Acquisition Subsidiary Number 3, Inc. 
 VHS Acquisition
Subsidiary Number 7, Inc. 
 VHS Acquisition Subsidiary Number 9, Inc. 

VHS Children’s Hospital of Michigan, Inc. 
 VHS Brownsville
Hospital Company, LLC 
 VHS Harlingen Hospital Company, LLC 

VHS Detroit Receiving Hospital, Inc. 
 VHS Harper-Hutzel Hospital,
Inc. 
 VHS Huron Valley-Sinai Hospital, Inc. 
 VHS of
Arrowhead, Inc. 
 VHS of Illinois, Inc. 

  
 I-2 

 VHS of Michigan, Inc. 

VHS of Phoenix, Inc. 
 VHS Rehabilitation Institute of Michigan,
Inc. 
 VHS San Antonio Partners, LLC 
 VHS Sinai-Grace
Hospital, Inc. 
 VHS West Suburban Medical Center, Inc. 
 VHS
Westlake Hospital, Inc. 
 VHS Valley Management Company, Inc. 

VHS Valley Health System, LLC 
 West Boca Medical Center, Inc.

  
 I-3Exhibit

Exhibit 10.1

SECOND AMENDMENT TO CREDIT AGREEMENT
This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of June 15, 2017 (this “Amendment”), is entered into by and among CSRA Inc. (formerly known as Computer Sciences Government Services Inc.), a Nevada corporation (the “Company”), the Guarantors listed on the signature pages hereto, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as administrative agent for the Lenders under the Pro Rata Facilities (in such capacity, the “Pro Rata Administrative Agent”), Royal Bank of Canada, as administrative agent for the Lenders under the Term Loan B Facility (in such capacity, the “Term Loan B Administrative Agent” and, together with the Pro Rata Administrative Agent, the “Administrative Agents”), the Replacement Term Loan B Lenders (as defined below) and the Incremental Term Loan B Lenders (as defined below).  Unless otherwise indicated, all capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to such terms in the Credit Agreement (as defined below).
W I T N E S S E T H:
WHEREAS, pursuant to the Credit Agreement, dated as of November 27, 2015 (as amended by the First Amendment to Credit Agreement dated as of November 30, 2016 and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”; and the Credit Agreement, as amended by this Amendment, the “Amended Credit Agreement”), among the Company, the Guarantors party thereto, the Lenders party thereto, the Administrative Agents, MUFG Union Bank, N.A., as collateral agent for the Secured Parties (in such capacity, the “Collateral Agent”), and the other Persons party thereto, the Lenders named therein have extended certain credit facilities to the Company.
WHEREAS, the Company has requested that (i) The Bank of Tokyo-Mitsubishi UFJ, Ltd., MUFG Union Bank, N.A., MUFG Securities Americas Inc. and their respective affiliates and (ii) RBC Capital Markets, as joint lead arrangers and joint bookrunners (collectively, the “Lead Arrangers”), arrange Replacement Advances in an aggregate principal amount of $466,328,381.46 (the “Replacement Term Loan B Advances”) pursuant to Section 9.01 of the Credit Agreement, the proceeds of which will be used to make a voluntary prepayment in full of the balance of the aggregate principal amount of the existing Term Loan B Advances outstanding immediately prior to the Second Amendment Effective Date (as defined below) (the “Existing Term Loan B Advances”).
WHEREAS, each institution listed on Schedule I hereto as a Replacement Term Loan B Lender (each, a “Replacement Term Loan B Lender”) (i) has agreed, on the terms and conditions set forth herein and in the Credit Agreement, to provide the amount of the Replacement Term Loan B Advances set forth opposite its name under the heading “Replacement Term Loan B Commitment” on Schedule I hereto (the “Replacement Term Loan B Commitment”) and (ii) by executing a signature page to this Amendment, approves of the amendments to the Credit Agreement as set forth in Section 5 hereof.
WHEREAS, each Term Loan B Lender holding Existing Term Loan B Advances (each, an “Existing Term Loan B Lender”) that executes and delivers a consent in the form of the Lender Consent attached to the Election Notice Memorandum (as defined in the Cashless Roll Letter (as defined below)) (a “Lender Consent”) will be deemed (i) to have agreed to the terms of this 

Amendment and the Amended Credit Agreement, (ii) to have agreed to exchange (as further described in the Lender Consent) the Allocated Amount (as defined in the Cashless Settlement of Existing Term Loan B Advances letter dated as of the date hereof (the “Cashless Roll Letter”), by and among the Company, the Replacement Term Loan B Lenders and the Term Loan B Administrative Agent) of its Existing Term Loan B Advances for Replacement Term Loan B Advances in an equal principal amount and (iii) upon the Second Amendment Effective Date, to have exchanged (as further described in the Lender Consent) the Allocated Amount of its Existing Term Loan B Advances for Replacement Term Loan B Advances in an equal principal amount, which will be effectuated either by exercising a cashless exchange option or through a cash settlement option selected by such Existing Term Loan B Lender in its Lender Consent.
WHEREAS, the Company has requested that the Lead Arrangers arrange Incremental Term Loan B Advances in an aggregate principal amount of $183,671,618.54 (the “Incremental Term Loan B Advances” and, together with the Replacement Term Loan B Advances, the “2017 Term Loan B Advances”) pursuant to Section 2.20(c) of the Credit Agreement (the “Incremental Term Loan B Financing”), the proceeds of which will be used for general corporate purposes.
WHEREAS, each institution listed on Schedule II hereto as an Incremental Term Loan B Lender (each, an “Incremental Term Loan B Lender”) (i) has agreed, on the terms and conditions set forth herein and in the Credit Agreement, to provide the amount of the Incremental Term Loan B Advances set forth opposite its name under the heading “Incremental Term Loan B Commitment” on Schedule II hereto (the “Incremental Term Loan B Commitment”) and (ii) by executing a signature page to this Amendment, approves of the amendments to the Credit Agreement as set forth in Section 5 hereof.
NOW THEREFORE, in consideration of the premises, the terms and conditions contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.References.  The rules of construction specified in Section 1.03 of the Credit Agreement also apply to this Amendment.  Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement” and each other similar reference contained in the Credit Agreement or any other Loan Document shall, after this Amendment becomes effective, refer to the Amended Credit Agreement.
2.    Replacement Term Loan B Advances.
(a)    Subject to the terms and conditions set forth herein, each Replacement Term Loan B Lender agrees to make Replacement Term Loan B Advances to the Company on the Second Amendment Effective Date in a principal amount not to exceed its Replacement Term Loan B Commitment.  Unless previously terminated, the Replacement Term Loan B Commitment shall terminate at 5:00 p.m., New York City time, on the Second Amendment Effective Date.Commencing on the Second Amendment Effective Date, for all purposes under the Amended Credit Agreement and the other Loan Documents, (i) the Replacement Term Loan B Advances shall be “Term Loan B Advances” and (ii) each Replacement Term Loan B Lender shall be a “Term Loan B Lender” with outstanding “Term Loan B Advances” under the Amended Credit Agreement.

2

3.    Incremental Term Loan B Advances.
(a)    Subject to the terms and conditions set forth herein, each Incremental Term Loan B Lender agrees to make Incremental Term Loan B Advances to the Company on the Second Amendment Effective Date in a principal amount not to exceed its Incremental Term Loan B Commitment.  Unless previously terminated, the Incremental Term Loan B Commitment shall terminate at 5:00 p.m., New York City time, on the Second Amendment Effective Date.
(b)    Commencing on the Second Amendment Effective Date, for all purposes under the Amended Credit Agreement and the other Loan Documents, (i) the Incremental Term Loan B Advances shall be “Term Loan B Advances” and (ii) each Incremental Term Loan B Lender shall be a “Term Loan B Lender” with outstanding “Term Loan B Advances” under the Amended Credit Agreement.
4.    Certain Agreements.
(a)    The Company shall repay to the Term Loan B Administrative Agent, for the account of the Term Loan B Lenders, (i) on each Term Loan B Repayment Date commencing with September 30, 2017 and ending on December 31, 2022, an amount equal to $500,000, (ii) on each Term Loan B Repayment Date thereafter, an amount equal to $2,375,000 (in the case of each of clauses (i) and (ii), which amounts shall be reduced as a result of the application of voluntary or mandatory prepayments made pursuant to Section 2.06(b) or 2.06(c) of the Amended Credit Agreement in the order specified by the Company in the applicable notice of prepayment; provided that if the Company fails to make any such specification, any voluntary or mandatory prepayments made pursuant to Section 2.06(b) or 2.06(c) of the Amended Credit Agreement shall be applied in direct chronological order to all then-remaining payments) and (iii) the then outstanding principal amount of the 2017 Term Loan B Advances on the Term Loan B Maturity Date.
(b)    The initial Interest Period with respect to the 2017 Term Loan B Advances shall commence on the Second Amendment Effective Date and end on the last day of the Interest Period then applicable to the Existing Term Loan B Advances (or, if there shall be more than one such Interest Period, with the principal amounts of the 2017 Term Loan B Advances apportioned among such Interest Periods in the same proportions as the Existing Term Loan B Advances are then apportioned).
5.    Amendments to Credit Agreement.  Effective as of the Second Amendment Effective Date (or, solely in the case of Section 5(e) hereof, the date that is five Business Days following the Second Amendment Effective Date), the Credit Agreement is hereby amended as follows:
(a)    Section 1.01 of the Credit Agreement is hereby amended by adding the following definitions in appropriate alphabetical order:
“Existing Credit Agreement” means the Original Credit Agreement, as amended by the First Amendment and as otherwise amended, restated, amended and restated, supplemented or otherwise modified prior to the Second Amendment Effective Date.

3

“Second Amendment” means that certain Second Amendment to Credit Agreement dated as of June 15, 2017 by and among the Company, the Guarantors party thereto, the Lenders party thereto, the Pro Rata Administrative Agent, the Term Loan B Administrative Agent and the Collateral Agent.
“Second Amendment Effective Date” means the date on which the conditions set forth in Section 6 of the Second Amendment have been satisfied, which date is June 15, 2017.
(b)    The definition of “Applicable Margin” in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:
“Applicable Margin” means, as at any date of determination, (i) with respect to Revolving Loan Advances, Tranche A1 Advance and Tranche A2 Advances, the interest rate per annum derived by dividing (x) the sum of the applicable Daily Margins for each of the days included in such period by (y) the number of days included in such period and (ii) with respect to Term Loan B Advances, (x) 1.00%, in the case of Base Rate Advances and (y) 2.00%, in the case of Eurocurrency Rate Advances.  For the avoidance of doubt, (i) at any time prior to the First Amendment Effective Date, the Applicable Margin shall be determined in accordance with the Original Credit Agreement and (ii) at any time from and after the First Amendment Effective Date and prior to the Second Amendment Effective Date, the Applicable Margin shall be determined in accordance with the Existing Credit Agreement.
(c)    The proviso in the definition of “Base Rate” in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:
“provided that, in the case of the Term Loan B Advances only, the Base Rate shall at no time be less than 1.00% per annum.”
(d)    The second proviso in the definition of “Eurocurrency Rate” in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:
“provided that the Eurocurrency Rate shall at no time be less than 0% per annum.”
(e)    Clause (h) of the definition of “Indebtedness” is hereby amended by replacing the reference therein to “Guaranteed Obligations” with “Guarantee Obligations”.
(f)    The definition of “Term Loan B Advance” is hereby amended by adding at the end thereof the following sentence: 
“The aggregate amount of Term Loan B Advances outstanding on the Second Amendment Effective Date is $650,000,000.”
(g)    Section 2.06(c)(ii) of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

4

“(ii)    In the event any Term Loan B Advances are subject to a Repricing Event prior to the six month anniversary of the Second Amendment Effective Date, a Term Loan B Lender whose Term Loan B Advances are prepaid or repaid in whole or in part, or which is required to assign any of its Term Loan B Advances pursuant to Section 2.17, in connection with such Repricing Event or which holds a Term Loan B Advance the Effective Yield of which is reduced as a result of a Repricing Event shall be paid an amount equal to 1.00% of the aggregate principal amount of such Term Loan B Lender’s Term Loan B Advances so prepaid, repaid, assigned or repriced.”
6.    No Other Amendments.  The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Administrative Agents, the Collateral Agent or the Lenders under the Credit Agreement or any of the other Loan Documents, nor constitute a waiver of any provision of the Credit Agreement or any of the other Loan Documents.  Except for the amendments set forth herein, the text of the Credit Agreement and all other Loan Documents shall remain unchanged and in full force and effect and the Company hereby ratifies and confirms its obligations thereunder.  Nothing in this Amendment is intended, or shall be construed, to constitute a novation or an accord and satisfaction of any of the Obligations or to modify, affect or impair the perfection or continuity of the Administrative Agents’, the Collateral Agent’s or the Lenders’ security interests in, security titles to, or other Liens on, any Collateral for the Obligations.
7.    Conditions to Effectiveness.  This Amendment and the amendments to the Credit Agreement contained in Section 5 (other than Section 5(e)) hereof shall become effective as of the first date when, and only when, each of the following conditions has been met or duly waived by each of the Administrative Agents, the Replacement Term Loan B Lenders and the Incremental Term Loan B Lenders in writing (such date, the “Second Amendment Effective Date”):
		
	(a)
	the Administrative Agents shall have received:

		
	(i)
	from the Company, each Guarantor, each Replacement Term Loan B Lender and each Incremental Term Loan B Lender, either (A) a counterpart of this Amendment signed on behalf of such party or (B) written evidence satisfactory to the Pro Rata Administrative Agent (which may include facsimile or other electronic transmission of a signed counterpart of this Amendment) that such party has signed a counterpart of this Amendment;

		
	(ii)
	a certificate of the Secretary or an Assistant Secretary or other authorized officer of the Company and each Guarantor, dated the Second Amendment Effective Date, (A) either (x) certifying the names and true signatures of the officers of the Company and such Guarantor, as the case may be, authorized to sign this Amendment and any other documents to be delivered by the Company or such Guarantor hereunder or (y) certifying that there has been no change to the officers of the Company and such Guarantor, as the case may be, authorized to sign Loan Documents and any other documents to be delivered by the Company or such Guarantor since the incumbency certificate delivered on the Closing Date or the First Amendment Effective Date, as the 

5

case may be, (B) either (x) attaching and certifying the correctness and completeness of the copies of the Company’s and such Guarantor’s Certificate of Incorporation and Bylaws or Certificate of Formation and Limited Liability Company Agreement or (y) certifying that there has been no change to such Certificate of Incorporation and Bylaws or Certificate of Formation and Limited Liability Company Agreement since last delivered on the Closing Date or the First Amendment Effective Date, as the case may be, (C) attaching and certifying the correctness and completeness of copies of the resolutions of the Board of Directors or similar governing body of each of the Company and each Guarantor, approving the execution, delivery and performance of this Amendment, and (D) attaching a good standing certificate of the Company and each Guarantor from the state of its organization, each dated a recent date prior to the Second Amendment Effective Date;
		
	(iii)
	customary legal opinions of (i) Davis Polk & Wardwell LLP, New York counsel to the Loan Parties, (ii) Woodburn and Wedge, special Nevada counsel to the Loan Parties and (iii) McGuire Woods LLP, special Virginia counsel to the Loan Parties, in each case, dated the Second Amendment Effective Date and consistent with the opinions provided on the First Amendment Effective Date;

		
	(iv)
	a certificate from an authorized financial officer of the Company in the form of Exhibit H to the Credit Agreement certifying as to the solvency of the Company and its Subsidiaries on a consolidated basis after giving effect to the incurrence of the 2017 Term Loan B Advances and the prepayment of the Existing Term Loan B Advances on the Second Amendment Effective Date;

		
	(v)
	a Notice of Borrowing in accordance with Section 2.02 of the Credit Agreement with respect to the 2017 Term Loan B Advances; and

		
	(vi)
	the payment of all fees and expenses payable to the Administrative Agents and the Lead Arrangers in connection with the execution and delivery of this Amendment, including, without limitation, to the extent invoiced at least two Business Days prior to the Second Amendment Effective Date, reimbursement or payment of all out-of-pocket expenses (including reasonable fees, charges and disbursements of counsel to the Administrative Agents) required to be reimbursed or paid by the Company under this Amendment;

		
	(b)
	the Administrative Agents and the Lenders shall have received all documentation and other information reasonably requested with respect to the Company and any Guarantor in writing by any Lender at least 10 Business Days in advance of the Second Amendment Effective Date, which documentation or other information is 

6

required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including the USA PATRIOT Act; and
		
	(c)
	substantially concurrently with the incurrence of the Replacement Term Loan B Advances, (i) unless otherwise subject to an election for cashless rollover from Existing Term Loan B Advances to Replacement Term Loan B Advances, 100% of the proceeds thereof shall have been applied to repay all of the Existing Term Loan B Advances and (ii) each Existing Term Loan B Lender shall have received payment of all accrued and unpaid interest owing to such Existing Term Loan B Lender in respect of its Existing Term Loan B Advances.

The amendment to the Credit Agreement set forth in Section 5(e) hereof shall become effective without any further action or consent of any party on the date that is five Business Days following the Second Amendment Effective Date, unless the Majority Lenders have objected in writing to such amendment on or prior to such date.
8.    Representations and Warranties.  Each Loan Party hereby represents and warrants that (i) it has taken all necessary corporate, partnership or limited liability action, as applicable, to authorize it to execute, deliver and perform its obligations under this Amendment (including under the Amended Credit Agreement) in accordance with the terms hereof and to consummate the transactions contemplated hereby, (ii) each representation and warranty made by such Loan Party hereunder or under any Loan Document is true and correct in all material respects (unless any such representation and warranty is qualified as to materiality, in which case such representation and warranty shall be true and correct in all respects, and unless such representation and warranty is made as of an earlier date, in which case such representation and warranty shall have been true and correct in all material respects as of such earlier date) as of the Second Amendment Effective Date, both before and after giving effect to the effectiveness of this Amendment and (iii) no Default or Event of Default has occurred and is continuing.  This Amendment is a valid and binding obligation of each Loan Party, enforceable against such Loan Party in accordance with its terms, subject to the effect of applicable bankruptcy, insolvency, arrangement, moratorium and other similar laws affecting creditors’ rights generally, concepts of reasonableness and the application of general principles of equity (regardless of whether such enforcement is considered in a proceeding in equity or at law).
9.    Acknowledgment of Security Interests.  Each Loan Party hereby acknowledges that, as of the date hereof, the security interests and liens granted to the Collateral Agent under the Credit Agreement and the other Loan Documents are in full force and effect and are enforceable in accordance with the terms of the Credit Agreement and the other Loan Documents, subject to the effect of applicable bankruptcy, insolvency, arrangement, moratorium and other similar laws affecting creditors’ rights generally, concepts of reasonableness and the application of general principles of equity (regardless of whether such enforcement is considered in a proceeding in equity or at law).
10.    Reaffirmation of Guarantees and Loan Documents.  Each Guarantor hereby reaffirms its guaranty of the Obligations pursuant to the Credit Agreement and hereby acknowledges that it has reviewed the terms and provisions of this Amendment and consents to this Amendment.  Each 

7

Loan Party hereby confirms that each Loan Document to which it is a party or is otherwise bound will continue to be in full force and effect as amended by this Amendment and, except as expressly set forth in this Amendment, all of its obligations thereunder shall not be impaired or limited by the execution or effectiveness of this Amendment.
11.    Consent to Assignment.  For purposes of Section 9.07(b) of the Amended Credit Agreement, the Company and the Term Loan B Administrative Agent hereby consent to the assignment of any 2017 Term Loan B Advances held by the Replacement Term Loan B Lenders or the Incremental Term Loan B Lenders, as applicable, on the Second Amendment Effective Date; provided that the Company consents to such assignment only to the extent that the amount and relative assignee of each such assignment has been disclosed by the Replacement Term Loan B Lenders or the Incremental Term Loan B Lenders, as applicable, to, and approved by, the Company on or prior to the Second Amendment Effective Date.
12.    Governing Law.  This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York. 
13.    Loan Document.  This Amendment shall be deemed to be a Loan Document for all purposes. 
14.    Severability.  In case any provision in or obligation under this Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 
15.    Counterparts.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
[Signature pages follow.]

8

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.
		
	COMPANY:
	CSRA INC., as the Company

By:  /s/ David F. Keffer     
Name:  David F. Keffer
Title:  Executive Vice President and 
Chief Financial Officer

[Signature Page to the Second Amendment]

		
	GUARANTORS:
	CSRA LLC (f/k/a CSC Government Solutions LLC), as a Guarantor

By:  /s/ Kevin M. Libby     
Name:  Kevin M. Libby
Title:  Vice President and Treasurer
STAR SECOND MERGER SUB LLC, as a Guarantor
By:  /s/  David P. Loose    
Name:  David P. Loose
Title:  Vice President and Treasurer
STERLING PARENT LLC, as a Guarantor
By:  /s/  David P. Loose    
Name:  David P. Loose
Title:  Vice President and Treasurer
SRA INTERNATIONAL, INC., as a Guarantor
By: /s/ David F. Keffer     
Name:  David F. Keffer
Title:  Executive Vice President and 
Chief Financial Officer

[Signature Page to the Second Amendment]

		
	AGENTS:
	THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., as Pro Rata Administrative Agent

By:  /s/ Lawrence Blat     
Name:   Lawrence Blat
Title:  Authorized Signatory
ROYAL BANK OF CANADA, as Term Loan B Administrative Agent
By:  /s/  Susan Khokher     
Name:  Susan Khokher 
Title:  Manager, Agency

[Signature Page to the Second Amendment]

ROYAL BANK OF CANADA, 
as Replacement Term Loan B Lender
By:  /s/ Theodore Brown    
Name:  Theodore Brown
Title:  Authorized Signatory
ROYAL BANK OF CANADA, 
as Incremental Term Loan B Lender
By:  /s/ Theodore Brown    
Name:  Theodore Brown
Title:  Authorized Signatory

[Signature Page to the Second Amendment]

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., 
as Replacement Term Loan B Lender
By:  /s/ Yen Hua    
Name:  Yen Hua    
Title:  Director
THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., 
as Incremental Term Loan B Lender
By:  /s/ Yen Hua    
Name:  Yen Hua    
Title:  Director

[Signature Page to the Second Amendment]

SCHEDULE I
Replacement Term Loan B Commitment
	
		
	Replacement Term Loan B Lender
	Replacement Term Loan B Commitment

	Royal Bank of Canada
	$233,164,190.73

	The Bank of Tokyo-Mitsubishi UFJ, Ltd.
	$233,164,190.73

	Total
	$466,328,381.46

SCHEDULE II
Incremental Term Loan B Commitment
	
		
	Incremental Term Loan B Lender
	Incremental Term Loan B Commitment

	Royal Bank of Canada
	$91,835,809.27

	The Bank of Tokyo-Mitsubishi UFJ, Ltd.
	$91,835,809.27

	Total
	$183,671,618.54

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]